Warning: This site requires Javascript to be enabled in order to function as expected.

#smooth-wrapper { height: auto !important; }

Skip to content

Tangram Therapeutics | Committed to uniting computation, RNAi, and unconventional thinking to make better medicines faster.

Press release

Notification of Full Year Results Date

6 May 2021

e-therapeutics plc will announce its full year results for the year ended 31 January 2021 on Thursday 13 May 2021.

Tags

Share
Sign up for press releases

Discover

Whats New?

Press release

Tangram Therapeutics Announces Progression to Patient Cohorts in Phase 1/2 RESTORE-MASH Trial of TGM-312 and Appointment of Dr Sonya Montgomery as Chief Development Officer

Sep 3, 2026

Press release

Tangram Therapeutics Announces Appointment of Laura Roca-Alonso, Ph.D. as Interim Chief Executive Officer

Mar 30, 2026

Press release

Tangram Therapeutics Announces First Participant Dosed in Phase 1/2 RESTORE-MASH Trial of TGM-312, a Novel Investigational RNAi Medicine

Mar 5, 2026

Press release

Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate

Nov 26, 2025

Press release

Tangram Therapeutics to Participate in Upcoming Investor and Scientific Conferences

Oct 3, 2025

Press release

e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS

Oct 1, 2025

/